Advertisement
Research Article

Phase 1 Trial of AMA1-C1/Alhydrogel plus CPG 7909: An Asexual Blood-Stage Vaccine for Plasmodium falciparum Malaria

  • Gregory E. D. Mullen mail,

    greg.mullen@kcl.ac.uk (GEDM); ellisru@niaid.nih.gov (RDE)

    Affiliation: Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America

    X
  • Ruth D. Ellis mail,

    greg.mullen@kcl.ac.uk (GEDM); ellisru@niaid.nih.gov (RDE)

    Affiliation: Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America

    X
  • Kazutoyo Miura,

    Affiliation: Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America

    X
  • Elissa Malkin,

    Affiliation: PATH Malaria Vaccine Initiative, Bethesda, Maryland, United States of America

    X
  • Caroline Nolan,

    Affiliation: Department of Medicine, University of Rochester, Rochester, New York, United States of America

    X
  • Mhorag Hay,

    Affiliation: Department of Medicine, University of Rochester, Rochester, New York, United States of America

    X
  • Michael P. Fay,

    Affiliation: Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • Allan Saul,

    Affiliation: Novartis Vaccines Institute for Global Health S.r.l. (NVGH), Siena, Italy

    X
  • Daming Zhu,

    Affiliation: Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America

    X
  • Kelly Rausch,

    Affiliation: Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America

    X
  • Samuel Moretz,

    Affiliation: Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America

    X
  • Hong Zhou,

    Affiliation: Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America

    X
  • Carole A. Long,

    Affiliation: Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America

    X
  • Louis H. Miller,

    Affiliation: Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America

    X
  • John Treanor

    Affiliation: Department of Medicine, University of Rochester, Rochester, New York, United States of America

    X
  • Published: August 13, 2008
  • DOI: 10.1371/journal.pone.0002940

Viewed info

Cited info

Saved info

Discussed info

Questions or concerns about usage data? Please let us know.